Autoimmune diabetic patients undergoing allogeneic islet transplantation
Standard
Autoimmune diabetic patients undergoing allogeneic islet transplantation : are we ready for a regulatory T-cell therapy? / Gagliani, Nicola; Ferraro, Alessandra; Roncarolo, Maria Grazia; Battaglia, Manuela.
in: IMMUNOL LETT, Jahrgang 127, Nr. 1, 02.12.2009, S. 1-7.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Autoimmune diabetic patients undergoing allogeneic islet transplantation
T2 - are we ready for a regulatory T-cell therapy?
AU - Gagliani, Nicola
AU - Ferraro, Alessandra
AU - Roncarolo, Maria Grazia
AU - Battaglia, Manuela
PY - 2009/12/2
Y1 - 2009/12/2
N2 - Regulatory T cells (Tregs) are thought to be pivotal in controlling both autoimmune and allogeneic undesired immune responses. Recently, an extensive effort has been devoted to design clinical trials with Tregs in T cell-mediated diseases (such as autoimmune diseases or transplantation). Theoretically, this approach can be used also in patients with autoimmunity (e.g., type 1 diabetes) undergoing allogeneic transplantation (e.g., pancreatic islet transplant). However, in this latter case Tregs must control two distinct effector immune responses: a pre-existing response towards self-antigens and a de novo response induced by the newly transplanted allogeneic cells. In this review we summarize results supporting the use of Tregs in controlling either autoimmunity or allo-transplantation. We also provide our view on how Treg therapy can achieve the final goal of immunological tolerance in the extremely challenging clinical setting of type 1 diabetic subjects transplanted with allogeneic islets.
AB - Regulatory T cells (Tregs) are thought to be pivotal in controlling both autoimmune and allogeneic undesired immune responses. Recently, an extensive effort has been devoted to design clinical trials with Tregs in T cell-mediated diseases (such as autoimmune diseases or transplantation). Theoretically, this approach can be used also in patients with autoimmunity (e.g., type 1 diabetes) undergoing allogeneic transplantation (e.g., pancreatic islet transplant). However, in this latter case Tregs must control two distinct effector immune responses: a pre-existing response towards self-antigens and a de novo response induced by the newly transplanted allogeneic cells. In this review we summarize results supporting the use of Tregs in controlling either autoimmunity or allo-transplantation. We also provide our view on how Treg therapy can achieve the final goal of immunological tolerance in the extremely challenging clinical setting of type 1 diabetic subjects transplanted with allogeneic islets.
KW - Animals
KW - Autoimmunity
KW - Diabetes Mellitus, Type 1
KW - Graft Rejection
KW - Humans
KW - Immune Tolerance
KW - Immunotherapy, Adoptive
KW - Islets of Langerhans Transplantation
KW - T-Lymphocytes, Regulatory
KW - Transplantation, Homologous
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
KW - Review
U2 - 10.1016/j.imlet.2009.07.007
DO - 10.1016/j.imlet.2009.07.007
M3 - SCORING: Review article
C2 - 19643137
VL - 127
SP - 1
EP - 7
JO - IMMUNOL LETT
JF - IMMUNOL LETT
SN - 0165-2478
IS - 1
ER -